Senior Postdoctoral Research Scientist
Christina Dold is a senior postdoctoral research scientist at the Oxford Vaccine Group. During her primary degree in zoology, she developed an interest in infectious diseases, particularly the Neglected Tropical Diseases (NTDs). In 2010, Christina obtained her PhD in parasitology at Trinity College Dublin in which she focused on resistance to the NTD ascariasis. On completing her PhD, she gained further experience in immunology laboratories in Ireland and Boston whilst also undertaking various roles in science communication and tutoring. She is currently involved in a pre-clinical investigation of vaccines against serogroup B meningococcus.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Flaxman A. et al, (2021), Lancet, 398, 981 - 990
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.
Frater J. et al, (2021), Lancet HIV, 8, e474 - e485
The antigenic anatomy of SARS-CoV-2 receptor binding domain.
Dejnirattisai W. et al, (2021), Cell